Alternative Splicing and Leukemia Initiating Cells (ASLIC)
Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukaemia (AML) are frequent. It have been shown that some splicing variants had a prognostic value in AML.
AML are characterized by their propensity to relapse because of the persistence of leukaemia initiating cells (LICs).
The aim of this study is to determine the splice variants on AML initiator cells and define a splicing pattern.
研究概览
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
Pierre-Bénite、法国、69310
- 招聘中
- Service d'hématologie du Centre Hospitalier Lyon Sud
-
接触:
- Etienne PAUBELLE, MD, PhD
- 电话号码:+33 04 78 86 22 50
- 邮箱:Etienne.paubelle@chu-lyon.fr
-
接触:
- Erice WATTEL, MD, PhD
- 电话号码:+33 04 78 86 22 60
- 邮箱:eric.wattel@chu-lyon.fr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Age ≥ 18 years-old
- Patients treated at the south lyon hospital center
- Patients with a diagnosis of acute myeloid leukemia confirmed in cytology and whose involvement of the 11q23 locus was confirmed by in situ hybridization
- Patients for whom a sample is available in the cytogenetic laboratory of the south lyon hospital center
Exclusion Criteria:
None
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
Splicing variants
Sample of acute myeloid leukaemia primary cells
|
This is a biological study with primary samples without any intervention on patients.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Polymerase chain reaction
大体时间:1 month
|
Transcriptome analysis to determine the splicing variants on acute myeloid leukaemia initiator cells. The analysis will focus on the gene encoding ABCA3 transporter and genes known to be mutated in patients with acute myeloid leukemia (FLT3, NPM1, c-Kit, N et K-RAS). The duration of selection of samples is estimated to be one month. |
1 month
|
Ribonucleic acid sequencing
大体时间:1 month
|
Transcriptome analysis to determine the splicing variants on acute myeloid leukaemia initiator cells. The analysis will focus on the gene encoding ABCA3 transporter and genes known to be mutated in patients with acute myeloid leukemia (FLT3, NPM1, c-Kit, N et K-RAS). The duration of selection of samples is estimated to be one month. |
1 month
|
合作者和调查者
调查人员
- 首席研究员:Etienne PAUBELLE, MD, PhD、Service d'hématologie du Centre Hospitalier Lyon Sud
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
急性髓性白血病的临床试验
-
Shenzhen Second People's Hospital招聘中白血病 | 骨髓的 | 慢性的 | BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) | 积极的中国